Review article: Refractory distal colitis - Explanations and options

Alimentary Pharmacology and Therapeutics

Volumn 10, Issue 1, 1996, Pages 39-48

  Griffin, M G ^a   Miner, P B ^a  

^a UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHISTAMINIC AGENT; AZATHIOPRINE; CLONIDINE; CYCLOSPORIN A; MERCAPTOPURINE; MESALAZINE; METHOTREXATE; OLSALAZINE; SALAZOSULFAPYRIDINE;

COLITIS; CROHN DISEASE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RECTAL DRUG ADMINISTRATION; REVIEW;

ADMINISTRATION, RECTAL; ANTI-INFECTIVE AGENTS; COLITIS, ULCERATIVE; DRUG RESISTANCE, MULTIPLE; IMMUNITY, NATURAL; IMMUNOSUPPRESSIVE AGENTS; SULFASALAZINE;

EID: 0030026791     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2036.1996.tb00175.x     Document Type: Review

References (97)

1. Farmer RG, Easley KA, Rankin GB. Clinical patterns, natural history and progression of ulcerative colitis: a long-term follow-up of 1116 patients. Dig Dis Sci 1993; 38: 1137-46.
2. Jenkins D, Goodall A, Scott BB. Ulcerative colitis: one disease or two (quantitative histological differences between distal and extensive disease). Gut 1990; 31: 426-30.
3. Roediger WEW. Role of anaerobic bacteria in the metabolic welfare of the colonic mucosa in man. Gut 1980; 21: 793-8.
4. Rao SS, Read NW, Brown C, Bruce C, Holdsworth CD. Studies on the mechanism of bowel disturbance in ulcerative colitis. Gastroenterol 1987; 93: 934-40.
5. King T, Biddle W, Bhatia P, Moore J, Miner PB. Colonic mucosal mast cell distribution at the line of demarcation of active ulcerative colitis. Dig Dis Sci 1992; 37: 490-5.
6. King TM, Biddle WL, Miner PB. Distribution of colonic mucosal mast cells in patients with ulcerative colitis in remission. Gastroenterol 1991; 100: A221.
7. Dileepan KN, Simpson KM, Stechschulte DJ. Modulation of macrophage superoxide-induced cytochrome c reduction by mast cells. J Lab Clin Med 1989; 113: 577-85.
8. Dileepan KN, Lorsbach RB, Stechschulte DJ. Mast cell granules inhibit macrophage-mediated lysis of mastocytoma cells (P815) and nitric oxide production. J Leukocyte Biol 1993; 53: 446-53.
9. 99mTc-labeled 5-ASA suppositories. Dig Dis Sci 1987; 32: 71S-5S.
10. Campieri M, Lanfranchi GA, Brignola C, et al. Retrograde spread of 5-aminosalicylic acid enemas in patients with active ulcerative colitis. Dis Colon Rectum 1986; 29: 108-10.
11. van Buul MM, Mulder CJ, Wiltink EH, van Royen EA, Tytgat GN. Retrograde spread of therapeutic enemas in patients with inflammatory bowel disease. Hepatogastroenterol 1989; 36: 199-201.
12. Chapman NJ, Brown ML, Phillips SF, et al. Distribution of mesalazine enemas in patients with active distal ulcerative colitis. Mayo Clin Proc 1992; 67: 245-8.
13. Vitti RA, Meyers F, Knight LC, Siegel JA, Malmud LS, Fisher RS. Quantitative distribution of radiolabeled 5-aminosalicylic acid enemas in patients with left-sided ulcerative colitis. Dig Dis Sci 1989; 34: 1792-7.
14. Miner PB. Left-sided ulcerative colitis and ulcerative proctitis. In: Bayless TM, ed. Current Therapy in Gastroenterology and Liver Disease, 4th edn. St Louis, MO: Mosby, 1994: 382-6.
15. Petitjean O, Wendling JL, Tod M, et al. Pharmacokinetics and absolute rectal bioavailability of hydrocortisone acetate in distal colitis. Aliment Pharmacol Ther 1992; 6: 351-7.
16. Schwartz AG, Targan SR, Saxon A, Weinstein WM. Sulfasalazine-induced exacerbation of ulcerative colitis. New Engl J Med 1982; 306: 409-12.
17. Adler RD. Sulfasalazine-induced exacerbation of ulcerative colitis. New Engl J Med 1982; 307: 315.
18. Ruppin H, Domschke S. Acute ulcerative colitis: a rare complication of sulfasalazine therapy. Hepatogastroenterol 1984; 31: 192-3.
19. Chakraborty TK, Bhatia D, Heading RC, Ford MJ. Salicylate induced exacerbation of ulcerative colitis. Gut 1987; 28: 613-5.
20. Shanahan F, Targan S. Sulfasalazine and salicylate-induced exacerbation of ulcerative colitis. New Engl J Med 1987; 317: 455.
21. Sturgeon JB, Bhatia PS, Hermens DJ, Miner PB. Exacerbation of chronic ulcerative colitis with mesalazine. Gastroenterol 1995; 108: 1889-93.
22. Faber SM, Korelitz BI. Crohn's proctitis: a previously undescribed entity. Gastroenterol 1990; 98: A168.
23. Langevin S, Menard DB, Haddad H, Beaudry R, Poisson J, Devroede G. Idiopathic ulcerative proctitis may be the initial manifestation of Crohn's disease. J Clin Gastroenterol 1992; 15: 199-204.
24. Singleton JW, Hanauer SB, Gitnick GL, et al. Mesalazine capsules for the treatment of active Crohn's disease: results of a 16-week trial. Gastroenterol 1993; 104: 1293-1301.
25. Tjandra JJ, Fazio VW, Petras RE. Clinical and pathologic factors associated with delayed diagnosis in solitary rectal ulcer syndrome. Dis Colon Rectum 1993; 36: 146-53.
26. Niv Y, Bat L. Solitary rectal ulcer syndrome - clinical, endoscopic and histological spectrum. Am J Gastroenterol 1986; 81: 486-91.
27. Harries AD, Jones L, Heatley RV, Rhodes J. Smoking habits and inflammatory bowel disease: effect on nutrition. Br Med J 1982; 284: 1161.
28. Motley RJ, Rhodes J, Ford GA, et al. Time relationships between cessation of smoking and onset of ulcerative colitis. Digestion 1987; 37: 125-7.
29. de Castella H. Non-smoking: a feature of ulcerative colitis. Br Med J 1982; 284: 1706.
30. Rudra T, Motley R, Rhodes J. Does smoking improve colitis? Scand J Gastroenterol 1989; 24 (Suppl. 170): 61-3.
31. Ravi S, Keat AC, Keat EC. Colitis caused by non-steroidal anti-inflammatory drugs. Postgrad Med J 1986; 62: 773-6.
32. Gibson GR, Whitacre EB, Ricotti CA. Colitis induced by nonsteroidal anti-inflammatory drugs: report of four cases and review of the literature. Arch Intern Med 1992; 152: 625-32.
33. Bjarnason I, Hayllar J, MacPherson AJ, Russell AS. Side effects of nonsteroidal anti-inflammatory drugs on the small and large intestine in humans. Gastroenterol 1993; 104: 1832-47.
34. Aabakken L, Osnes M. Non-steroidal anti-inflammatory drug-induced disease in the distal ileum and large bowel. Scan J Gastroenterol 1989; 24 (Suppl. 163): 48-55.
35. Rampton DS, Sladen GE. Relapse of ulcerative proctocolitis during treatment with non-steroidal anti-inflammatory drugs. Postgrad Med J 1981; 57: 297-9.
36. Walt RP, Hawkey CJ, Langman MJ. Colitis associated with non-steroidal anti-inflammatory drugs. Br Med J 1984; 288: 238.
37. Kaufmann H, Taubin HL. Nonsteroidal anti-inflammatory drugs activate quiescent inflammatory bowel disease. Ann Intern Med 1987; 107: 513-6.
38. Riley SA, Mani V, Goodman MJ, Lucas S. Why do patients with ulcerative colitis relapse? Gut 1990; 31: 179-83.
39. Oshitani N, Kitano A, Nakamura S, Matsumoto T, Kobayaski K. Factors in relapse of ulcerative colitis. Gastroenterol 1992; 102: A676.
40. Minoli G, Imperiali G, Terruzzi V, et al. Biphasical annual periodicity in ulcerative colitis relapses. Gastroenterol 1993; 104: A746.
41. Kirschner BS. Does acute infection trigger chronic inflammation in pediatric patients with chronic inflammatory bowel disease? Gastroenterol 1993; 104: A725.
42. Kangro HO, Chong SK, Hardiman A, Heath RB, Walker-Smith JA. A prospective study of viral and mycoplasma infections in chronic inflammatory bowel disease. Gastroenterol 1990; 98: 549-53.
43. Hermens DJ, Miner PB. Exacerbation of ulcerative colitis. Gastroenterol 1991; 101: 254-62.
44. Isgar B, Harman M, Kaye MD, Whorwell PJ. Symptoms of irritable bowel syndrome in ulcerative colitis in remission. Gut 1983; 24: 190-2.
45. Bayless TM, Harris ML. Inflammatory bowel disease and irritable bowel syndrome. Med Clin North Am 1990; 74: 21-8.
46. Mogadam M, Korelitz BI, Ahmed SW, Dobbins WO, Baiocco PJ. The course of inflammatory bowel disease during pregnancy and postpartum. Am J Gastroenterol 1981; 75: 265-9.
47. Present DH, Korelitz BI, Wisch N, Glass JL, Sachar DB, Pasternak BS. Treatment of Crohn's disease with 6-mercaptopurine: a long-term, randomized, double-blind study. N Engl J Med 1980; 302: 981-7.
48. Adler DJ, Korelitz BI. The therapeutic efficacy of 6-mercaptopurine in refractory ulcerative colitis. Am J Gastroenterol 1990; 85: 717-22.
49. Steinhart AH, Baker JP, Brzezinski A, Prokipchuk EJ. Azathioprine therapy in chronic ulcerative colitis. J Clin Gastroenterol 1990; 12: 271-5.
50. Kozarek RA, Patterson DJ, Gelfand MD, Botoman VA, Ball TJ, Wilske KR. Methotrexate induces clinical and histologic remission in patients with refractory inflammatory bowel disease. Ann Intern Med 1989; 110: 353-6.
51. Kozarek RA, Patterson DJ, Gelfand MD, Ball TJ, Botoman VA. Long-term use of methotrexate in inflammatory bowel disease: severe disease 3, drugs therapy 2, seventh inning stretch. Gastroenterol 1992; 102: A648.
52. Feagan BG, Rochon J, Fedorak RN, et al. Methotrexate for the treatment of Crohn's disease. N Engl J Med 1995; 332: 292-7.
53. Lichtiger S, Present DH. Cyclosporin A in the treatment of severe ulcerative colitis. Gastroenterol 1992; 102: A653.
54. Lichtiger S, Present DH, Kornbluth A, et al. Cyclosporin in severe ulcerative colitis refractory to steroid therapy. N Engl J Med 1994; 330: 1841-5.
55. Present DH. Cyclosporine and other immunosuppressive agents: current and future role in the treatment of inflammatory bowel disease. Am J Gastroenterol 1993; 88: 627-30.
56. Kozarek RA. Review article: immunosuppressive therapy for inflammatory bowel disease. Aliment Pharmacol Ther 1993; 7: 117-23.
57. Brynskow J, Freund L, Thomsen OO, Andersen CB, Rasmussen SN, Binder V. Treatment of refractory ulcerative colitis with cyclosporin enemas. Lancet 1989; 1: 721-2.
58. Ranzi R, Campanini MC, Belio P, Di Palo FQ, Bianchi P. Treatment of chronic proctosigmoiditis with cyclosporin enemas. Lancet 1989; 2: 97.
59. Sandborn WJ, Tremaine WJ, Schroeder KW, Steiner BL, Batts KP, Lawson GM. Cyclosporine enemas for treatment-resistant, mildly to moderately active, left-sided ulcerative colitis. Am J Gastroenterol 1993; 88: 640-5.
60. Winter T, Dalton HR, Merrett MN, Campbell A, Jewell DP. Cyclosporin A retention enemas in refractory distal ulcerative colitis: an open trial. Gastroenterol 1992; 102: A947.
61. Sandborn WJ, Tremaine WJ, Schroeder KW, et al. A placebo-controlled trial of cyclosporine enemas for mild to moderately left-sided ulcerative colitis. Gastroenterol 1994; 106: 1429-35.
62. Harig JM, Soergel KH, Komorowski RA, Wood CM. Treatment of diversion colitis with short-chain fatty-acid irrigation. New Engl J Med 1989; 320: 23-28.
63. Breuer RI, Suto SK, Christ ML, et al. Rectal irrigation with short-chain fatty acids for distal ulcerative colitis: preliminary report. Dig Dis Sci 1991; 36: 185-7.
64. Sheppach W, Sommer H, Kirchner T, et al. Effect of butyrate enemas on the colonic mucosa in distal ulcerative colitis. Gastroenterol 1992; 103: 51-6.
65. Senagore AJ, MacKeigan JM, Scheider M, Ebrom JS. Short-chain fatty-acid enemas: a cost-effective alternative in the treatment of nonspecific proctosigmoiditis. Dis Colon Rectum 1992; 35: 923-7.
66. Harris ML, Schiller HJ, Reilly PM, Donowitz M, Grisham MB, Bulkley GB. Free radicals and other reactive oxygen metabolites in inflammatory bowel disease: cause, consequence or epiphenomenon? Pharmacol Ther 1992; 53: 375-408.
67. Williams JG, Hughes LE, Hallett MB. Toxic oxygen metabolite production by circulating phagocytic cells in inflammatory bowel disease. Gut 1990; 31: 187-93.
68. Emerit J, Pelletier S, Tosoni-Verlignue D, Mollet M. Phase II trial of copper zinc superoxide dismutase (CuZnSOD) in treatment of Crohn's disease. Free Rad Biol Med 1989; 7: 145-9.
69. Hoski K, Oka H, Haramot S. Clinical application of liposomal SOD in several intractable diseases. Medical, biochemical and chemical aspects of free radicals. In: Proceedings of the Fourth Biennial General Meeting of the Society for Free Radical Research. London: Elsevier Science, 1988, 731-4.
70. Flohe L. Superoxide dismutase for therapeutic use: clinical experience, dead ends and hopes. Molec Cell Biochem 1988; 84: 123-31.
71. Aruoma OI, Wasil M, Halliwell B, Hoey BM, Butler J. The scavenging of oxidants by sulphasalazine and its metabolites: a possible contribution to their anti-inflammatory effects? Biochem Pharmac 1987; 36: 3739-42.
72. Yamada T, Volkmer C, Grisham MB. Anti-oxidant properties of 5-ASA: potential mechanism for its anti-inflammatory activity. Can J Gastroenterol 1990; 4: 295-302.
73. Salim AS. Role of oxygen-derived free radical scavengers in the management of recurrent attacks of ulcerative colitis: a new approach. J Lab Clin Med 1992; 119: 710-7.
74. Bennet JD. Use of alpha-tocopherylquinone in the treatment of ulcerative colitis. Gut 1986; 27: 695-7.
75. Shanahan F. Inflammatory bowel disease. In: Targan SR, moderator. Immunologic Mechanisms in Intestinal Diseases. 862-6. Ann Intern Med 19878; 106: 853-70.
76. Shanahan F, Anton P. Neuroendocrine modulation of the immune system. Dig Dis Sci 1988; 33 (Suppl.): 41S-9S.
77. Reichlin S. Neuroendocrine-immune interactions. New Engl J Med 1993; 329: 1246-53.
78. Stead RH, Dixon MF, Bramwell NH, Riddell RH, Bienenstock J. Mast cells are closely apposed to nerves in the human gastrointestinal mucosa. Gastroenterol 1989; 97: 575-85.
79. Galli SJ. New concepts about the mast cell. N Engl J Med 1993; 328: 257-65.
80. McCafferty CM, Wallace JL, Sharkey KA. Beneficial effects of lidocaine in experimental colitis: a neurogenic component of inflammation? Gastroenterol 1993; 104: A739.
81. Bjorck S, Dahlstrom A, Ahlman H. Topical treatment of ulcerative proctitis with lidocaine. Scand J Gastroenterol 1989; 24: 1061-72.
82. Schiller LR, Santa Ana CA, Morawski SG, Fordtran JS. Studies of the antidiarrheal action of clonidine: effects on motility and intestinal absorption. Gastroenterol 1985; 89: 982-8.
83. Fondacaro JD, Kolpak D, McCafferty GP. Selective alpha-2 adrenoceptor agonists alter fluid and electrolyte transport in mammalian small intestine. J Pharm Exp Therap 1988; 247: 481-6.
84. Lechin F, van der Dijs B, Insausti CL, et al. Treatment of ulcerative colitis with clonidine. J Clin Pharmacol 1985; 25: 219-26.
85. Melander M, Almer S, Strom M. Clonidine in ulcerative colitis and proctitis. J Intern Med 1993; 233: 93-4.
86. Pullan RD, Rhodes J, Ganesh S, et al. Transdermal nicotine for active ulcerative colitis. N Engl J Med 1994; 330: 811-5.
87. Rao SS, Read NW, Davison PA, Bannister JJ, Holdsworth CD. Anorectal sensitivity and response to rectal distention in patients with ulcerative colitis. Gastroenterol 1987; 93: 1270-5.
88. Whitehead WE, Holtkotter B, Enck P, et al. Tolerance for rectosigmoid distention in irritable bowel syndrome. Gastroenterol 1990; 98: 1187-92.
89. Libel R, Biddle WL, Miner HB. Evaluation of anorectal physiology in patients with increased mast cells. Dig Dis Sci 1993; 38: 877-81.
90. Burleigh DE, D'Mello A. Neural and pharmacologic factors effecting motility of the internal anal sphincter. Gastroenterol 1983; 84: 409-17.
91. Plourde V, Lembo T, Shue Z, et al. Effects of the somatostatin analogue octreotide on rectal afferent nerves in humans. Am J Physiol 1993; 265: G742-51.
92. Gaffney PR, Doyle CT, Hogan J, Gaffney A. Paradoxical response to heparin in 10 patients with ulcerative colitis. Gastroenterol 1993; 104: A703.
93. Lucio J, D'Brot J, Guo C, et al. Immunologic mast cell-mediated responses and histamine release are attenuated by heparin. J Appl Physiol 1992; 73: 1093-101.
94. Inase N, Schreck RE, Lazarus SC. Heparin inhibits histamine release from canine mast cells. Am J Physiol 1993; 264: L387-90.
95. Kochhar R, Mehta SK, Aggarwal R, Dhar A, Patel F. Sucralfate patient in ulcerative rectosigmoid lesions. Dis Colon Rectum 1990; 33: 49-51.
96. Knoflach H, Muller C, Eibl MM. Crohn's disease and intravenous immunoglobulin G. Ann Intern Med 1990; 112: 385-6.
97. Jarlov AE, Munkholm P, Norblad Schmidt P, Langholz E, Faber Vestergaard B, Molskov Bech R. Treatment of active distal ulcerative colitis with immunoglobulin G enemas. Aliment Pharmacol Ther 1993; 7: 561-5.